Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy
about
Pathogenesis beyond the cancer clone(s) in multiple myeloma.The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib.Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro.Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.Regulation of NKT Cell Localization in Homeostasis and InfectionLeptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma.A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progressionA case of refractory multiple myeloma with proliferation of large granular lymphocytes by lenalidomide treatment and its association with clinical efficacy.Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies.Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma.Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation.Deficient invariant natural killer T cells had impaired regulation on osteoclastogenesis in myeloma bone disease.
P2860
Q35607266-18B6537C-62FA-4EFF-BCFE-759AAA1EC76BQ35669068-DE28056C-2A92-4006-8D3A-2866756A3CF0Q36060298-A1925EB9-27CD-4FDF-8FA2-2F839911BF06Q37012554-EAFFFCE0-65A9-4258-816C-21513BFCB33AQ38462720-DF98263D-73F8-4C37-A0A8-CCCA37F082A2Q38527820-A6BB9D5D-A950-4D6E-A50E-957D7D2DA0FDQ38793607-C71999E1-8BB2-4F78-9F15-8A9E86110649Q38797097-91F8E0D7-2942-4204-BC58-5415F5B2CC8DQ39136762-734977D9-547B-429D-BB22-5FC08DDD70EAQ39654083-4F70F902-15D6-45E3-AA04-36C119473FBFQ43555934-04D35E69-D1E4-442B-A050-7A20E387560CQ52668568-4E5F6A48-F2C8-48A5-A6E8-2172F719ACEBQ53073922-7907C5CF-ED03-4082-AB64-96681395BD44Q54213159-43BD2FE3-9B22-4F88-904E-D483E68D2562Q55236874-CC92CD25-28F8-4551-A270-32C6A96210FB
P2860
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy
@en
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy
@nl
type
label
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy
@en
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy
@nl
prefLabel
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy
@en
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy
@nl
P2093
P2860
P50
P356
P1476
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy
@en
P2093
P2860
P356
10.1111/CEI.12196
P407
P577
2014-01-01T00:00:00Z